Associated tags: Atopic dermatitis, Ulcerative colitis, Asthma, UC, Antibody, Itch, Patient, SAN, Pharmaceutical industry, CNTB, Inflammation, Safety, Week, Vaccine, Entrepreneurship
Locations: AD
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m.
Key Points:
- SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m.
- ET.
- Please see below for additional details about the event and how to request a one-on-one meeting with management.
- Registration and 1x1 Meeting Requests: Click Here
Retrieved on:
Monday, February 12, 2024
SAN,
Connect,
Investment,
Marketing,
Amgen,
Atopic dermatitis,
Johnson & Johnson,
Asthma,
Bristol Myers Squibb,
Eos,
CNTB,
University,
Therapy,
Business,
Patient,
KPCB,
GSK plc,
Chemical engineering,
Kleiner Perkins,
Pharmaceutical industry James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.
Key Points:
- James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.
- “We are thrilled to welcome James to Connect’s Board of Directors,” said Wubin (Bill) Pan, Ph.D., M.B.A., Co-Founder, President, and Chairman of the Board of Connect Biopharma.
- “His breadth of biotech and investment experience, coupled with his passion for innovative and transformative life science companies will provide our Board with a unique perspective.
- Additionally, Mr. Huang serves as a director on the board of directors of a number of companies, including Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, Eos, GT Aperion, Domain, Asia Pacific Medical and XWPharma.
Retrieved on:
Tuesday, December 12, 2023
Patient,
Entrepreneurship,
Atopic dermatitis,
Food,
Allergy,
Internal medicine,
Asthma,
ACQ,
Freedom,
Wheeze,
Week,
COVID-19,
Periodic breathing,
Congress,
Webcast,
Cough,
Pharmaceutical industry Improvement was evident as early as Week 1 and statistically significant starting at Week 2 through Week 24 for both doses of rademikibart.
Key Points:
- Improvement was evident as early as Week 1 and statistically significant starting at Week 2 through Week 24 for both doses of rademikibart.
- Additionally, there were strong trends toward prolonging the time to first exacerbation in both rademikibart groups compared to placebo.
- “We are thrilled with the results of our global Phase 2b study in asthma showing clinically meaningful and sustained improvement in lung function with both high and low doses of rademikibart showing improvement as early as Week 1,” commented Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma.
- “In the Phase 2b global asthma trial, strong efficacy data was seen in the rademikibart groups, with improvements in airflow and daily asthma symptoms observed rapidly within the first week of treatment.
Retrieved on:
Monday, December 11, 2023
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open.
Key Points:
- SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open.
- Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m.
- ET to discuss the top-line data.
- The call will feature a discussion with Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.
Retrieved on:
Tuesday, November 21, 2023
These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.
Key Points:
- These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.
- “This study demonstrated that rademikibart has a best-in-class potential, and if approved as a Q4W treatment, we believe could offer patients with AD a highly efficacious treatment with less frequent dosing than current approved treatments.
- I’d like to thank the patients, their families, the clinical and manufacturing teams, and all of our vendors that were an integral part of this trial.
- Patients that did not achieve EASI-50 (non-responders) were assigned to an open label Q2W rademikibart arm (n=86).
Retrieved on:
Tuesday, November 21, 2023
“We are delighted to enter this strategic partnership with Simcere for the development and commercialization of rademikibart in Greater China concurrently with reporting our strong long-term efficacy and safety top-line data from the rademikibart China pivotal trial in AD” said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma.
Key Points:
- “We are delighted to enter this strategic partnership with Simcere for the development and commercialization of rademikibart in Greater China concurrently with reporting our strong long-term efficacy and safety top-line data from the rademikibart China pivotal trial in AD” said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma.
- “Simcere is a leading pharmaceutical company in China with an extensive partnership track record and proven capabilities in regulatory affairs, manufacturing, clinical operations, and commercialization.
- Simcere has been granted exclusive rights to develop, manufacture and commercialize rademikibart for all indications in Greater China, including mainland China, Hong Kong, Macau, and Taiwan, while Connect Biopharma retains rights in all other markets.
- “We are very excited to have reached this agreement with Connect Biopharma.
Retrieved on:
Monday, November 20, 2023
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) on Tuesday, November 21, 2023, prior to market open.
Key Points:
- SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) on Tuesday, November 21, 2023, prior to market open.
- Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m.
- ET to discuss the trial results.
Retrieved on:
Tuesday, September 12, 2023
Insurance,
Maintenance,
Asthma,
American Academy of Dermatology,
Week,
Center for Drug Evaluation and Research,
New Drug Application,
NDA,
American Academy,
Atopic dermatitis,
Research,
CNTB,
Polyp (medicine),
USD,
Ulcerative colitis,
Accounting,
Congress,
UC,
Patient,
AAD,
Spirometry,
Investment,
SAN,
CDE,
Sinusitis,
Entrepreneurship,
Cytokine,
R,
AD,
FDA,
Type 2 inflammation,
FEV1,
RMB,
Safety,
Pharmaceutical industry,
Vaccine,
Medical imaging,
Cryptocurrency,
Dermatology SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the six months ended June 30, 2023 and provided a business update.
Key Points:
- SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the six months ended June 30, 2023 and provided a business update.
- “We also reported positive long-term data from the Phase 2 maintenance period in ulcerative colitis with our other late-stage asset – icanbelimod.
- There were no new safety signals and icanbelimod continued to be well-tolerated, consistent with observed induction period safety data.
- Published in July 2023 the pre-clinical data characterizing rademikibart in Nature’s Scientific Reports.
Retrieved on:
Tuesday, September 12, 2023
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 11, 2024, to regain compliance.
Key Points:
- In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 11, 2024, to regain compliance.
- The letter states that the Nasdaq staff will provide written confirmation that the Company has achieved compliance if at any time before March 11, 2024, the closing bid price of the Company’s ADSs closes is at least $1.00 per share or more for a minimum of ten consecutive business days.
- If the Company does not regain compliance by March 11, 2024, the Company may be eligible for an additional 180 calendar day compliance period.
- To qualify, the Company would be required to first transfer to the Nasdaq Capital Market and then meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period.
Retrieved on:
Thursday, August 24, 2023
SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma’s management team will participate at the following upcoming investor conferences:
Key Points:
- SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma’s management team will participate at the following upcoming investor conferences:
The Connect Biopharma management team will host one-on-one meetings during the conferences.
- Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
- Links to access company presentation for select events, when available, will be posted to Connect Biopharma’s website on the Presentations & Events page of the Investors section.
